Elaine Siegfried

Dr. Elaine Siegfried


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2016 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
ESElaine Siegfried
Elaine Siegfried
JJJennifer C. Jaworski
Jennifer C. Jaworski
JKJennifer D. Kaiser
Jennifer D. Kaiser
AHAdelaide A. Hebert
Adelaide A. Hebert
Many clinicians have concerns about the safety of atopic dermatitis (AD) treatments, particularly in children requiring long-term daily maintenance therapy. Topical corticosteroids (TCS) have been widely used for >5 decades. Long-term TCS monotherapy has been associated with adverse cutaneous effects including atrophy, rebound flares, and increased percutaneous absorption with potential for adverse systemic effects. Topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, available for 1–2 decades, are not associated with atrophy or increased percutaneous absorption after prolonged use and have much lower potential for systemic effects. However, since 2006 TCIs have carried a controversial Boxed Warning based on a theoretical risk of malignancy (eg, skin and lymphoma) that has limited TCI use for standard-of-care maintenance therapy. A comparative systematic search of PubMed was done for long-term (≥12 week) clinical trials of TCS or TCI treatment in patients <12 years with AD. Citations were reviewed for inclusion based on MeSH terms, abstracts, and relevant article text. Studies were excluded if they did not encompass subjects <12 years, or were <12 weeks’ duration, retrospective, meta-analyses, or limited to anecdotal case reports. Of 27 trials meeting criteria, 21 included 5825 pediatric patients treated with TCIs, and 6 included 1999 patients treated with TCS. TCS studies were limited to low- to mid-potency products, and all but one study lacked a vehicle control. Eight TCI studies were vehicle-controlled, and safety data were well reported, with ≤5 % of patients reporting discontinuation due to adverse effects (DAEs). Cutaneous and systemic adverse events (AEs) were similar in TCI and vehicle groups, with no reports of lymphoma. Safety data in TCS trials were less well reported. DAE incidence was addressed in just 2 trials, and systemic and cutaneous AEs were mostly unreported. Data supporting long-term use of TCIs are robust, documenting safety and efficacy, while data supporting long-term TCS use are limited to low- to mid-potency products. Our review identifies a lack of information on the safety of commonly prescribed, long-term monotherapy with mid- to high-potency TCS in pediatric AD, and supports standard-of-care maintenance therapy with TCIs and intermittent use of low- to mid-potency TCS for flares.

24 May 2013 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
ESElaine Siegfried
Elaine Siegfried
JJJennifer C. Jaworski
Jennifer C. Jaworski
AHAdelaide A. Hebert
Adelaide A. Hebert
Topical calcineurin inhibitors (TCIs), commercially available since 2000–2001, are the first and only topical medications approved for chronic treatment of atopic dermatitis (AD) in pediatric patients and remain a welcomed alternative to topical corticosteroids. In January 2006, the US Food and Drug Administration (FDA) issued a boxed warning requirement based on a theoretical risk of malignancy (including lymphoma) with TCI use. However, in the years since, analyses of epidemiologic and clinical data have failed to demonstrate a causal relationship between TCI use and malignancy or lymphoma risk, especially for pimecrolimus cream. In fact, the observed number of malignancies and lymphomas observed both in post-marketing surveillance and reported to the FDA using its adverse events reporting system is much lower among TCI-exposed patients than the expected number for the general population. Furthermore, among children enrolled in post-marketing pediatric registry studies for both tacrolimus and pimecrolimus followed for up to 5.5 years [10,724 patient-years (PY)] or 6.5 years (16,219 PY), respectively, the observed number of malignancies and lymphomas is very low and similar to the number expected for a sample of similar size in the general population. In addition to reporting these comparative malignancy and lymphoma data, this article provides a historical overview of the boxed warning requirement and critically evaluates the preclinical, clinical, and epidemiological evidence that has thus far failed to substantiate a relationship between TCI use and malignancy. The authors also provide practical clinical advice for optimizing AD management and patient care in the context of the boxed warning.

Verified
Journal Article
Open access
PDF file
ESElaine Siegfried
Elaine Siegfried
AHAdelaide A. Hebert
Adelaide A. Hebert
Atopic dermatitis (AD) is one of the most common skin diseases affecting infants and children. A smaller subset of adults has persistent or new-onset AD. AD is characterized by pruritus, erythema, induration, and scale, but these features are also typical of several other conditions that can mimic, coexist with, or complicate AD. These include inflammatory skin conditions, infections, infestations, malignancies, genetic disorders, immunodeficiency disorders, nutritional disorders, graft-versus-host disease, and drug eruptions. Familiarity of the spectrum of these diseases and their distinguishing features is critical for correct and timely diagnosis and optimal treatment.

4 January 2018 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
LELawrence F. Eichenfield
Lawrence F. Eichenfield
APAmy S. Paller
Amy S. Paller
WTWynnis L. Tom
Wynnis L. Tom
JSJeffrey Sugarman
Jeffrey Sugarman
AHAdelaide A. Hebert
Adelaide A. Hebert
KCKelly M. Cordoro
Kelly M. Cordoro

21 July 2014 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
BPBrea Prindaville
Brea Prindaville
RARichard J. Antaya
Richard J. Antaya
ESElaine Siegfried
Elaine Siegfried

1 November 2010 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
ESElaine Siegfried
Elaine Siegfried
LELawrence F. Eichenfield
Lawrence F. Eichenfield
Amy PallerAmy Paller
Amy Paller
DPDavid Pariser
David Pariser
KCKara Creamer
Kara Creamer
GKGregory Kricorian
Gregory Kricorian